Inclusion Criteria:  Age>=18Y Good Organ Function Expected survival time ≥ 3 months Metastatic/recurrent advanced BRAF+ mCRC that have been diagnosed histologically and have failed first line treatment ECOG score 0-1;  Exclusion Criteria:  arm 1 ： Previous treatment with BRAF inhibitors or MEK inhibitors Symptomatic brain or meningeal metastases (unless the patient has been on > treatment for 3 months, has no evidence of progress on imaging within 4 weeks prior to initial administration, and tumor-related clinical symptoms are stable). Active clinical severe infection; A history of other malignancies within two years, except for cured carcinoma in situ of the cervix or basal cell carcinoma of the skin.